Erythrocyte PIG‐A mutant frequencies in cancer patients receiving cisplatin
Open Access
- 12 January 2024
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 13 (3)
Abstract
Background: Cisplatin is a primary chemotherapy choice for various solid tumors. DNA damage caused by cisplatin results in apoptosis of tumor cells. Cisplatin‐induced DNA damage, however, may also result in mutations in normal cells and the initiation of secondary malignancies. In the current study, we have used the erythrocyte PIG‐A assay to evaluate mutagenesis in non‐tumor hematopoietic tissue of cancer patients receiving cisplatin chemotherapy.Methods: Twenty‐one head and neck cancer patients undergoing treatment with cisplatin were monitored for the presence of PIG‐A mutant total erythrocytes and the young erythrocytes, reticulocytes (RETs), in peripheral blood for up to five and a half months from the initiation of the anti‐neoplastic chemotherapy.Results: PIG‐A mutant frequency (MF) in RETs increased at least two‐fold in 15 patients at some point of the monitoring, while the frequency of total mutant RBCs increased at least two‐fold in 6 patients. A general trend for an increase in the frequency of mutant RETs and total mutant RBCs was observed in 19 and 18 patients, respectively. Only in one patient did both RET and total RBC PIG‐A MFs did not increase at any time‐point over the monitoring period.Conclusion: Cisplatin chemotherapy induces moderate increases in the frequency of PIG‐A mutant erythrocytes in head and neck cancer patients. Mutagenicity measured with the flow cytometric PIG‐A assay may serve as a tool for predicting adverse outcomes of genotoxic antineoplastic therapy.Keywords
This publication has 35 references indexed in Scilit:
- Persistence of Cisplatin-Induced Mutagenicity in Hematopoietic Stem Cells: Implications for Secondary Cancer Risk Following ChemotherapyToxicological Sciences, 2014
- International Pig‐a gene mutation assay trial: Evaluation of transferability across 14 laboratoriesEnvironmental and Molecular Mutagenesis, 2011
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- Interlaboratory Pig‐a gene mutation assay trial: Studies of 1,3‐propane sultone with immunomagnetic enrichment of mutant erythrocytesEnvironmental and Molecular Mutagenesis, 2011
- Monitoring humans for somatic mutation in the endogenous pig‐a gene using red blood cellsEnvironmental and Molecular Mutagenesis, 2011
- When pigs fly: Immunomagnetic separation facilitates rapid determination of Pig-a mutant frequency by flow cytometric analysisMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2011
- The in vivo pig‐a gene mutation assay, a potential tool for regulatory safety assessmentEnvironmental and Molecular Mutagenesis, 2010
- The use of PIG-A as a sentinel gene for the study of the somatic mutation rate and of mutagenic agents in vivoMutation Research - Reviews in Mutation Research, 2010
- Protection of erythrocytes from human complement–mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapyBlood, 2006
- Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuriaCytometry, 2000